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Immunotherapy has emerged as an important thera peutic modality for a broad range of cancer types. Antibodies targeting the T cell inhibitory receptors cytotoxic T lymphocyte antigen 4 (CTLA4) and pro grammed death receptor 1 (PD1) (or its ligand PDL1) are the most clinically advanced, with US Food and Drug Administration (FDA) approvals in melanoma, nonsmallcell lung cancer (NSCLC), renal cell carci noma, bladder cancer, Hodgkin lymphoma, head and neck cancer, Merkel cell carcinoma, microsatellite insta ble (MSI)high tumours, hepatocellular carcinoma and gastrooesophageal junction cancer [1] [2] [3] [4] . Despite these exciting advances and broad applicability of the drugs, only a minority of patients with cancer benefit from these therapies 3, 5 . Analysis of pretreatment tumour biopsy samples from patients treated with checkpoint blockade therapy and/or with therapeutic cancer vac cines has revealed that patients with a preexisting local CD8 + T cell infiltrate (T cell-inflamed) were more likely to show a clinical response (data presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting 6 and in REFS 2, 5, [7] [8] [9] [10] . Approximately 35% of metastatic melanoma lesions have gene expres sion profiles indicative of a T cellinflamed tumour microenvironment (TME) phenotype. These profiles are present in a subset of patients of most cancer types, as shown by analysis of The Cancer Genome Atlas (TCGA) data [11] [12] [13] . These baseline biomarker data are consistent with the notion that checkpoint blockade therapy (in particular antiPD1) is efficacious largely through reactivation of tumour antigenspecific T cells already present within the TME 5, 14 . However, the majority of solid tumours do not show evidence of a productive T cell infiltrate and can be characterized as non-T cell-inflamed 11, 15 . Mechanistic studies into the events that trigger spontaneous antitumour T cell priming have high lighted critical steps. Initial CD8 + T cell priming against tumourassociated antigens occurs via basic leucine zipper transcriptional factor ATF-like 3 lineage dendritic cells (BATF3 DCs), which are capable of crosspresenting tumourderived antigens through the class I major histo compatibility complex (MHC) pathway 16 . Mice deficient for BATF3 DCs fail to prime tumourspecific CD8 + T cells in vivo and fail to control growth of immunogenic tumour variants 17, 18 . Studies in syngeneic tumour mouse models have indicated that tumourderived DNA acti vates the stimulator of interferon genes (STING) path way in dendritic cells (DCs) which, in turn, induces a type I interferon (IFN) cascade, both of which are impor tant for optimal T cell priming in vivo [19] [20] [21] [22] . In line with these findings, studies in human tumours have found that the presence of BATF3 DCs and induction of type I IFN correlate with T cell infiltration [23] [24] [25] . Following CD8 + T cell activation in the tumourdraining lymph node, CD8 + effector T cells traffic back to the inflamed TME in a CXCchemokine receptor 3 (CXCR3)dependent response to the chemokines CXCchemokine ligand 9 (CXCL9) and CXCL10 (REF. 26) (FIG. 1) . Notably, gene expression patterns indicative of each of these stages of productive antitumour immunity are characteristic of the T cellinflamed TME 
Checkpoint blockade therapy
Includes all therapies targeting immune inhibitory molecules or pathways mediating a decrease of T cell function within the tumour microenvironment. The most prominent examples are anticytotoxic T lymphocyte antigen 4 (CTLA4) and anti-programmed death receptor 1 (PD1) antibodies.
Impact of oncogenic pathways on evasion of antitumour immune responses
Stefani Spranger 1 and Thomas F. Gajewski 2, 3 Abstract | Immunotherapeutic interventions are showing effectiveness across a wide range of cancer types, but only a subset of patients shows clinical response to therapy. Responsiveness to checkpoint blockade immunotherapy is favoured by the presence of a local, CD8 + T cell-based immune response within the tumour microenvironment. As molecular analyses of tumours containing or lacking a productive CD8 + T cell infiltrate are being pursued, increasing evidence is indicating that activation of oncogenic pathways in tumour cells can impair induction or execution of a local antitumour immune response. This Review summarizes our current knowledge of the influence of oncogenic effects on evasion of antitumour immunity.
T cell-inflamed
A microenvironment in which CD8 + T cells are found within the tumour mass or the invasive margin of the tumour. T cells produce interferon γ (IFNγ) and other cytokines yet at the same time express immune inhibitory molecules on their surface, including programmed death receptor 1 (PD1).
Non-T cell-inflamed
A microenvironment that is representative of all tumour microenvironments with no evidence of an ongoing CD8 + T cell-driven immune response and lack of expression of key chemokines and cytokines. This group of tumours might be quite diverse.
Basic leucine zipper transcriptional factor ATF-like 3 lineage dendritic cells (BATF3 DCs). Cells defined by the expression of the transcription factors BATF3 and interferon regulatory factor 8 (IRF8). In mice, they express lineage markers CD8α and/or CD103 (also known as ITGAE), while in humans, they express thrombomodulin (TM; also known as CD141). This lineage of DCs has the capability to cross-present tumour-derived antigens to CD8 + T cells.
Oncogenic pathways
Tumour cell-intrinsic signalling pathways with a known capability to mediate tumour induction or progression from within the tumour cells themselves. They are often but not always associated with specific mutations in oncogenes or tumour suppressor genes.
On the basis of this working model, one might envi sion that the nonT cellinflamed TME might result from a block in one or more steps in this cascade of events. NonT cellinflamed tumours appear to pos sess a number of antigens similar to that of their T cell inflamed counterparts, thereby excluding reduced antigenicity as a predominant evasion mechan ism 11, 29 . Similarly, T cellinflamed and nonT cellinflamed tumour lesions can be present within the same patient, suggesting that in some cases, there are features within specific metastatic sites that might cause defective T cell infiltration [30] [31] [32] . These observations indicate that molecular alterations in specific tumour cell intrinsic molecular pathways might affect the degree of T cell infiltration into a given tumour. Indeed, increas ing clinical evidence suggests that activation of certain oncogenic pathways is associated with the nonT cell inflamed TME and the potential for immunotherapy resistance (data presented at the American Association for Cancer Research (AACR) Annual Meeting 2017 (REF. 33 ) and in REFS 31, 34) . This Review summarizes current knowledge on how oncogenic pathways, acti vated through gainoffunction alterations in oncogenes or lossoffunction alterations in tumour suppressor genes, influence the local antitumour immune response and highlights potential therapeutic solutions. 
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fl/fl GEMMs devel oped melanoma with 100% penetrance. However, further analysis revealed that βcateninpositive tumours had minimal T cell infiltration and were resistant to check point blockade therapy 13, 39 . Indeed, in βcateninpositive tumours, production of CCchemokine ligand 4 (CCL4) and other chemokines by melanoma cells was reduced, which at least partly caused a severely reduced recruit ment of BATF3 DCs into the TME. This led to defec tive host priming of antigenspecific T cells, causing resistance to checkpoint blockade therapy 13 . Indeed, therapy resistance could be reversed by injection of mature DCs into βcateninpositive tumours. Together, these data show that tumour cellintrinsic activation of βcatenin signalling could contribute to a nonT cell inflamed TME and cause resistance to checkpoint blockade immunotherapy in vivo 13 . Further studies revealed that the lack of effector T cell infiltration in βcatenin positive tumours was also due to defective effector T cell trafficking, which in βcateninnegative tumours was driven by the chemokines CXCL9 and CXCL10, produced mainly by BATF3 DCs. Thus, the absence of BATF3 DCs from βcateninpositive tumours caused defective early T cell priming as well as defective trafficking of effector T cells into the TME 40 . This is the reason why adoptive transfer of tumourspecific effector T cells or prophylactic vaccination inhibited growth of βcateninnegative tumours but failed to inhibit growth of βcatenin positive tumours 40 . These data demonstrate the possibility that upregulation of βcatenin and/or defective recruitment of BATF3 DCs can potentially mediate secondary resistance to immunotherapies The WNT-βcatenin pathway appears to be associ ated with a nonT cellinflamed TME in cancer types beyond melanoma, as suggested, for example, in studies on bladder cancer and head and neck cancer 41, 42 . In addi tion, an ongoing analysis of TCGA data across all solid tumour types has indicated a similar correlation between the nonT cellinflamed phenotype and gainoffunction of βcatenin signalling in tumour cells in the majority of tumour types included in the analysis (data presented Nature Reviews | Cancer at the 2016 ASCO Annual Meeting 43 ). This includes colorectal carcinoma (CRC), which typically has a high frequency of genetic alterations linked to βcatenin path way activation and at the same time shows rare clinical benefit of antiPD1 immunotherapy 44 . A recent study on the immune and stromal classification of CRC and its association with CRC molecular subtypes suggested that tumours of the MSI subtype and the mesenchymal subtype appeared T cellinflamed, while tumours of both the metabolic subtype and the canonical subtype appeared nonT cellinflamed 45 . In line with this dis tinction, both the MSI and the mesenchymal subtypes do not rely on activation of WNT-βcatenin signalling for tumour development, whereas the canonical and the metabolic subtypes rely on inactivation of the adeno matous polyposis coli gene for tumour development 46 .
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Figure 2 | Impact of oncogenic signalling on immune inhibitory pathways and cell populations. β-catenin: immune exclusion mediated by activation of the WNT-β-catenin pathway occurs when expression of CC-chemokine ligand 4 (CCL4) is inhibited and thus basic leucine zipper transcriptional factor ATF-like 3 lineage dendritic cells (BATF3 DCs) are no longer recruited into the tumour microenvironment. Consequently, owing to a lack of CXC-chemokine ligand 10 (CXCL10) production by BATF3 DCs, no T cell priming occurs, and effector T cells are not recruited into the tumour. MYC: activation of MYC signalling enhances the expression of leukocyte surface antigen CD47 and programmed cell death 1 ligand 1 (PDL1) on tumour cells through transcriptional regulation. Expression of these immune inhibitory molecules interferes with antigen uptake by antigen-presenting cells (APCs) via engagement with signal regulator protein-α (SIRPα) and inhibits T cell function via PD1 engagement, respectively. LKB1: loss of liver kinase B1 (LKB1) signalling within tumour cells results in increased expression of various cytokines, including interleukin-6 (IL-6), IL-33 and CXCL7. IL-6 mediates recruitment of neutrophils into the tumour microenvironment, an immunosuppressive cell type that contributes to reduced T cell infiltration and promotes T cell dysfunction. LKB1 mutations can also lead to activation of MYC signalling within the same tumour cells, providing potential crosstalk between pathways. PTEN: loss of PTEN protein function and thereby activation of PI3K inhibits lipidation of the autophagosome protein LC3 and autophagy in tumour cells, a process that can diminish T cell priming and also mediate resistance to T cell-mediated apoptosis. TP53: effector T cell exclusion from the tumour can occur owing to inactivating TP53 mutations, which results in reduced chemokine production by tumour cells. In particular, TP53-mutated tumour cells lack production of key chemokines required for the recruitment of natural killer (NK) cells and T cells, which is required for NK cell recruitment into the tumour microenvironment.
Moreover, patients with CRC who have tumours of the MSI subtype have high response rates to antiPD1 ther apy 47 . It is suggested that these high response rates of MSI tumours correlate with the potential for high levels of neoantigens in these tumours 48 . However, it remains to be shown whether the lack of βcatenin pathway activation in these tumours contributes to the clinical benefit of antiPD1 therapy. Of note, a case report from a patient with ovarian cancer described that activation of the WNT-βcatenin pathway in some metastatic lesions was associated with a lack of T cell infiltration and with a lack of response to checkpoint blockade therapy 31 . Prospective preclinical and clinical studies are ongoing to evaluate whether tumour cellintrinsic WNT-βcatenin signalling is associated with check point blockade resistance in larger cohorts of patients and whether targeting this pathway can be a potential strategy to improve immunotherapy outcomes (S.S. and T.F.G., unpublished data).
Gain of MYC function inhibits T cell activation and infiltration. The transcription factor MYC regulates cell proliferation, differentiation and survival and is overexpressed in many cancers 49, 50 . Most commonly, activation of the pathway occurs through gene ampli fication or constitutive expression rather than through point mutations 51 . Seminal work using a GEMM with conditionally regulated Myc, and in which Myc over expression leads to the development of osteogenic sar comas, showed that continuous overexpression of Myc was necessary to maintain tumour cell persistence, an observation known as 'oncogene addiction' (REF. 52 ). In the same model, when Myc was inactivated, tumour cells underwent cell cycle arrest and apoptosis, lead ing to improved animal survival 50 . Interestingly, sub sequent work revealed that host T cells significantly contributed to tumour cell elimination following Myc inactivation 53 . In particular, while CD4 + T cells were not required for the induction of cell cycle arrest following reactivation of Myc, CD4 + T cells were required for the induction of senescence 53 . Mechanistically, inactivation of Myc led to a marked decrease in the expression of PDL1, the dominant ligand for the inhibitory receptor PD1 on activated T cells, and leukocyte surface antigen CD47, which limits activation of antigenpresenting cells (APCs) through binding to signal regulator proteinα (SIRPα) on macrophages and DCs and blocking antigen uptake 54, 55 . PDL1 and CD47 transcription was controlled directly by MYC, and restoring CD47 or PDL1 expression by transfection reversed the pheno type and prevented accumulation of tumourassociated T cells 56 ( FIG. 2; TABLE 1 ). Restoring PDL1 or CD47 also led to stabilization of CD31 + microvessels and expres sion of the proangiogenic molecules tyrosineprotein kinase receptor TIE2 (also known as TEK) and angio tensin 1 (ANG1) in Mycinactivated tumours 56 . The connection between an active immune response and vessel stabilization should be further investigated as functional vasculature is important for extravasation of lymphocytes 26, 56 .
Loss-of-function alterations

Loss of LKB1 function decreases T cell infiltration.
In addition to immune evasion mechanisms linked to defective T cell priming, some tumourintrinsic pathways may mediate immune evasion through the recruitment of immune inhibitory cell populations. A key example is liver kinase B1 (LKB1; also known as STK11), a tumour suppressor gene that is mutated in approximately 30% of patients with NSCLC and has been associated with worse prognosis 57 . Analysis of the TME in a Krasdriven NSCLC GEMM engi neered either with or without Lkb1 deletion revealed a marked increase in tumourassociated neutrophils in Lkb1deficient tumours along with a modest decrease in the quantity of infiltrating T cells 58 . Phenotypic ana lysis of tumourinfiltrating lymphocytes (TILs) revealed decreased cytokine production and increased expression of PD1, hepatitis A virus cellular receptor 2 (HAVCR2; also known as TIM3) and lymphocyte activation gene 3 protein (LAG3), which is consistent with a dysfunc tional TIL state. Differential gene expression profil ing indicated that interleukin33 (IL33), CXCL7 and IL6 were expressed at higher levels by Lkb1deficient tumour cells. Functionally, depletion of neutrophils or blockade of IL6 resulted in increased T cell infiltration into Lkb1deficient tumours and improved efficacy of antiPD1 antibody therapy 58 (FIG. 2; TABLE 1) .
The mechanisms by which IL6 production is regu lated and how it interferes with antitumour immunity downstream are incompletely understood. Increased activation of the signal transducer and activator of tran scription 3 (STAT3) signalling pathway was observed in Lkb1deficient NSCLC tumours, which provides one 59 . Activation of some of these down stream factors is associated with an immune inhibitory phenotype in other cancer model systems (for exam ples, see MYC gainoffunction and other oncogenic pathways described above) and is worth investigating mechanistically in future experiments 56 .
Loss of PTEN reduces efficient T cell priming.
Inactivating mutations or deletion of PTEN has been associated with defective T cell infiltration in melano mas 60 . Interestingly, in tumours showing partial PTEN loss resulting in intratumoural heterogeneity, T cells were found to localize only to regions that retained PTEN expression 60 . In a mouse preclinical model, a PI3Kβ isoformpreferential inhibitor was therapeuti cally synergistic with immunotherapy in vivo, arguing that selective PI3K inhibitors might have the potential to augment immunotherapy effectiveness in the clinic as well. A separate study found that PI3K inhibitors could improve antiPD1 efficacy in a clinically relevant breast cancer mouse model 61 . In patients with melanoma who were treated with an antiPD1 monoclonal antibody (mAb), clinical response was favoured in patients show ing high PTEN expression in the tumour. Together, these data suggest that mutations or deletion of PTEN rep resent an immune evasion mechanism. A more recent study has linked deletion of specific regions of chromo some 10 that flank the PTEN gene with failed response to checkpoint blockade therapy 25 . The mechanism by which PTEN deletion and/or PI3K activation might promote immune eva sion is incompletely understood and could be multi factorial. Gene expression profiling revealed that CCL2 and vascular endothelial growth factor (VEGF) were elevated in melanoma patient samples harbouring PTEN loss, while expression of MHCI and PDL1 was unaffec ted 60 . In addition, a decrease in the expression of autophagyrelated genes was observed. This decrease in gene expression was accompanied by reduced auto phagic activity in melanomas with PTEN loss and in human melanoma cell lines with PTEN knockdown 60 . This finding is of interest because autophagy in cancer cells has been reported to contribute to T cell priming by increasing DC activation and crosspresentation follow ing tumour implantation in mice [62] [63] [64] . In particular, auto phagy was required for ATP release from tumour cells undergoing death in response to chemotherapy, thereby enabling ATPdependent DC recruitment 64 . In addi tion, tumour cellderived autophagosomes are able to trigger an immune response by delivering neoantigens to APCs 62, 63 . PTENdeficient melanoma cells were also more resistant to CD8 + T cellmediated killing in vitro 60 (FIG. 2) . Importantly, when autophagy was induced in these cells by overexpressing the gene microtubule associated protein 1 light chain 3 beta (MAP1LC3B), which encodes an important autophagosome protein, the susceptibility of PTENdeficient melanoma cells to T cellmediated killing was restored 60 . It remains to be investigated whether the reduced autophagic activ ity in PTENdeficient tumour cells is associated with a decrease in type I IFN induction and decreased T cell priming in the tumourdraining lymph node. Regardless of this critical mechanistic gap, the studies in melanomas with PTEN loss 60 have motivated clinical exploration of specific PI3K inhibitors in combination with checkpoint blockade immunotherapy 65 .
Loss of p53 function decreases T cell infiltration.
Inactivating mutations of the tumour suppressor gene Trp53 have been associated with reduced immune infiltration 66 . This study used an orthotopic tumour model in which a Hrasmutant mouse hepatoblast cell line was engineered to express a doxycyclineinducible, Trp53 targeting microRNA. Here, the growth of hepato carcinoma induced by Trp53 silencing could be inhibited upon doxycycline withdrawal and restoration of Trp53 expression 66 . Interestingly, gene expression profiling revealed that tumour regression was associated with increased expression of immune genes in the tumour cells. These genes included colony stimulating factor 1 (CSF1), CCL2, CXCL1 and IL-15 along with the adhesion molecules intercellular adhesion molecule 1 (ICAM1) and vascular cell adhesion molecule 1 (VCAM1) 66 . In an independent study using the same model, induc tion of Trp53 resulted in increased expression of CCL2, CCL3, CCL4, CCL5, CXCL1 and CXCL2 as well as the cytokines IL1β, IL12β and IL15 (REF. 67 ). In this model, tumour regression was mediated by natural killer (NK) cells and the membrane protein NKG2D expression rather than by T cell infiltration, arguing that oncogenic pathways might also influence innate lymphoidlike cells (FIG. 2; TABLE 1) .
A recent analysis of human tumours has also sug gested a correlation between p53 status and immune cell infiltrates 68 . Within a subset of basallike breast cancer samples, a correlation between loss of p53 function and absence of a T cell gene signature was observed. Patients with loss of heterozygosity as well as a p53 mutation showed the most profound decrease in T cell infiltra tion 68 . Within an oestrogen receptor (ER)negative cohort, similar results were observed, while ERpositive patients with breast cancer did not show any correlation between p53 loss and lack of T cell infiltration 68 . It will be interesting to investigate a range of additional tumour types to uncover similar associations in other cancers. Given the wide range of changes in chemokine produc tion associated with dysregulation of the p53 pathway, additional studies will be needed to investigate which immune cell types are affected in patients with distinct types of cancer.
Impact of other oncogenic pathways
Early data have suggested the potential for additional oncogenic pathways to affect antitumour immunity. Recent findings in patients with gliomas as well as in a preclinical glioma mouse model have provided evi dence that mutations in the genes encoding isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are associated with reduced T cell infiltration 69 . Initial investigation of samples from the TCGA database provided evi dence that tumours with activating mutations in IDH1 or IDH2 show reduced expression of cytotoxic T cell markers, including CD8A and IFNG. Further analy sis using an orthotopic model of glioma showed that tumour cells engineered to have mutated Idh1, leading to increased IDH1 activity, showed diminished recruit ment of T cells. Mechanistically, increased IDH1 activ ity led to reduced levels of STAT1 protein as well as reduced phosphorylated STAT1. Diminished STAT1 signalling in glioma cells was associated with reduced expression of CXCL10, a critical chemokine for effector T cell recruitment. Finally, exposure of tumour cells to an IDH1 inhibitor restored STAT1 signalling, CXCL10 expression and T cell infiltration in vivo 69 . The fact that IDH1 inhibitors are currently in clinical development raises the possibility of evaluating whether immune cell infiltration is augmented with these agents in human cancer patients 70 . The role of tumour cellintrinsic tyrosineprotein kinase JAK1-STAT1 signalling for immunemediated tumour control is in keeping with analysis of tumours isolated from patients with sec ondary resistance to antiPD1 therapy, in which muta tions in the IFNγ signalling pathway were observed in two cases. However, whether there is a direct connec tion between JAK1-STAT1 signalling and antiPD1 resistance and whether there is crosstalk with tumour oncogenic pathways remain unclear 24, 25, 71 . In contrast to the decreased STAT1 signalling described above, STAT3 signalling is frequently activated in human tumours 72 . In vitro studies have indicated that inhibition of STAT3 can generate a proinflammatory milieu, whereas augmentation of STAT3 signalling can decrease expression of proinflammatory medi ators, including the chemokines CCL5 and CXCL10 (REFS 73, 74) . This concept was supported in vivo using a genetically induced prostate cancer model, as well as in a model of carcinogeninduced NSCLC, indicat ing that oncogenic STAT3 signalling could modulate the immuno biology of the TME 75, 76 . In this prostate cancer model driven by Pten loss, tumour cells under went senescence and showed an increase in phos phorylated STAT3 (REF. 75) . Transcriptional activity by STAT3 induced the expression of chemokines and cytokines, including CXCL1, CXCL2 and macrophage CSF (MCSF), associated with the recruitment of myeloid derived suppressor cells (MDSCs). Ablation or inhibition of STAT3 signalling eliminated MDSC accu mulation and restored T cell accumulation within the tumour 75 . Whether alterations in STAT3 signalling and loss of PTEN function are frequently intertwined should be investigated in future studies.
Studies in bladder cancer have pointed to additional candidate oncogenic pathways linked to immune exclu sion. As in melanoma, βcatenin pathway activation was found in tumours within a nonT cellinflamed subset of bladder cancers. In addition, tumours of this nonT cellinflamed subset also contained fibroblast growth factor receptor 3 (FGFR3)activating muta tions 41 or evidence for peroxisome proliferatoractivated receptorγ (PPARγ)signalling activation 41 . A separate study has shown that bladder cancers can be subgrouped into those expressing high levels of claudin and those expressing low levels of claudin, which can be linked to the level of immune response 77 . Interestingly, tumours of the claudinlow subset expressed immune gene sig natures at high levels as well as genes consistent with active immunosuppression and had decreased frequen cies of FGFR3 mutations and PPARG amplification 77 , a finding in line with the observations described above regarding nonT cellinflamed bladder cancers. In addi tion, PPARγsignalling activation in bladder cancer has recently been linked to mutations in the nuclear hormone receptor gene retinoid X receptoralpha (RXRA), which encodes a cofactor of PPARγ 78 . These findings suggest the possibility of pharmacologic tar geting of this pathway as a strategy to improve immune cell infiltration.
Nuclear factorκB (NFκB) signalling has a variety of effects on tumour development and on the inter action with host stromal cells. For example, activation of the NFκB signalling pathway in tumour cells promotes tumorigenesis in inflammationinduced carcinogenesis models 79, 80 . In other settings, NFκB signalling might be an additional candidate oncogenic pathway that locally inhibits host immune responses. In inflammation induced cancer models, including CRC models, activa tion of NFκB signalling has indeed been associated with increased inflammation 81 , though by an extrinsic mech anism mediated through exogenous cytokines, such as tumour necrosis factor (TNF) 82 . Constitutive activation of NFκB within tumour cells also has been reported to increase the expression of specific chemokines in a transplantable colon cancer model, which could poten tially promote the immune response 81, 83 . In contrast to those studies, inhibition of NFκB signalling in lung adenocarcinoma cells resulted in increased chemokine production 84 . The frequent activation of NFκB signal ling in human cancers warrants further investigation into the potential impact on local antitumour T cell responses, for example, by using GEMMs. The overall effect of oncogenic NFκB might depend on the cellular context and the type of immune cells involved, either tumourpromoting inflammatory cells or antitumour adaptive immune cells.
Several of the abovementioned oncogenic pathways are intertwined with changes in oxygen availability and tumour cell metabolism. Recent studies in ovar ian and breast cancer have highlighted the impact of VEGF and cyclooxygenase 1 (COX1) and COX2 expres sion on the local antitumour immune response 85, 86 . These studies provide evidence that hypoxiamediated VEGF increased FASligand (FASL) expression on endothelial cells, in a COX1dependent manner, and thus induces T cell death during extravasation 85 . Similarly, hypoxia induced prostaglandin E2 (PGE2) and/or COX2 stress responses result in an unproductive IL6driven inflam matory response. Here, acetylsalicylic acid mediated inhibition of COX2 was found to be sufficient to a switch to an IFNγdriven antitumour response 86 . Similar to other oncogenic pathways, hypoxia is also associated with a reduction in recruitment and activation of BATF3 DCs, which would provide a mechanistic link to poor T cell infiltration 86 . Despite these interesting links between hypoxia and immune evasion, it remains unclear whether specific targetable oncogenic pathways are responsible for these processes. Many oncogenic pathways, such as the MYC pathway, regulate metabo lism in tumour tissue, which could potentially affect nutrient availability and enforce dysfunctional cellular metabolism in infiltrating immune cells, thereby affect ing the immune response 87 . For example, T cells increase their glycolytic flux upon activation, which might be impaired when glucose as fuel is limited 87 . In addition, HIF1 regulates a number of metabolic pathways and could affect immune cell metabolism and activity in the tumour 87 . However, whether metabolic dysregulation is directly linked to the degree of T cell infiltration in the tumour remains to be shown.
Lastly, epigenetic mechanisms may play a role in dif ferential tumour cell gene expression and thus immune cell infiltration. One example of such a mechanism is the regulation of chemokine gene expression in human ovarian cancer 88 . The gene loci for the chemokines CXCL9 and CXCL10 were found to be epigenetically silenced in ovarian tumour cells, which was associated with decreased effector T cell recruitment. It is con ceivable that expression of additional immunologically relevant genes might be similarly affected by epigenetic mechanisms, which remains to be investigated. If such a regulation is present, it would suggest that histone deacetylase inhibitors and/or DNA methyltransferase inhibitors have the potential to augment adaptive immu nity within the TME and expand the effectiveness of cancer immunotherapies.
Conclusions and outlook T cell infiltration into the TME is associated with an increased likelihood of immunotherapy efficacy, includ ing checkpoint blockade therapy. As such, understanding the molecular mechanisms that contribute to a reduction of effector T cell infiltration should enable the develop ment of novel agents that restore T cell infiltration and promote immunotherapy efficacy. Several of the bio chemical pathways identified to date that are linked to T cell exclusion are candidates for molecularly targeted therapy. For example, PI3K inhibitors are being investi gated for PTENdeficient tumours 65 . Because of the fact that PI3K is also involved in T cell activation, thoughtful dose and schedule regimens may have to be considered. Alternatively, isoformspecific PI3K inhibitors that favour tumour cellintrinsic activity with relative sparing of T cell functionality could be considered. As a general drug development paradigm, once a tolerable dose and schedule are obtained, then patients selected on the basis of expression of the relevant target in the tumour could be analysed for T cell infiltration. In addition, immune gene expression profiling on biopsy samples before and after treatment with the targeted agent could be carried out. It is interesting to consider that these drugs as single agents do not necessarily have to demonstrate clinical activity per se. Rather, once a given drug evidently pro motes a T cellinflamed TME, combination studies with immunotherapies such as antiPD1 or antiPDL1 mAbs could be rapidly developed. Some identified pathways, such as the WNT-βcatenin pathway, have been chal lenging to inhibit in a global fashion as the pathway has critical importance in normal tissues, such as bone and the gastrointestinal tract. Thus, new screens for agents that selectively restore the relevant immune gene targets while sparing global shutdown of certain pathways could be considered.
An alternative approach to promote de novo T cell activation and immune infiltration into the TME of nonT cellinflamed tumours is to leapfrog over the array of altered oncogenic pathways and restore the earliest ratelimiting step that appears to be absent from those tumours in general -that is, by restoring recruitment and activation of BATF3 DCs. For exam ple, direct intratumoural injection of activated BATF3 DCs has restored T cell infiltration in the βcatenin positive Braf LSL−V600E /Pten fl/fl GEMM 13, 40 . The activation of APCs using agonists of the cyclic GMPAMP synthase (cGAS)-STING pathway is also being considered, and the first STING agonist is currently in phase I clinical development 20, 89 . The early signs of success using intratu moural injection of oncolytic viruses, such as talimogene laherparepvec (TVec), which is FDA approved for mel anoma 90 , as well as additional similar approaches with engineered Coxsackie viruses, also indicate the potential of engaging innate immune pathways that could in prin ciple promote T cell priming and infiltration into 'cold' tumours, which are not responsive to immunotherapy 91 . An additional important consideration is intensifying the analysis of patients who develop secondary resist ance following initial clinical response to immunothera pies, such as antiPD1. Reanalysis of progressing lesions following initial clinical response should determine whether the selection for subsets of tumour cells with active immuneevasive oncogenic pathways might lead to secondary resistance as well.
